Medpace Holdings, Inc. $MEDP Stock Holdings Lessened by Nutshell Asset Management Ltd

Key Points

• Nutshell Asset Management cut its Medpace stake by 54.3% in Q3, selling 22,217 shares and ending the period with 18,712 shares (worth about $9.62 million), which represented roughly 4.6% of the firm's holdings and MEDP's 10th-largest position.
• Meanwhile, several large institutions (Wasatch, Mawer, AQR, Baillie Gifford, Epoch) increased their positions, leaving overall institutional ownership at 77.98%, signaling mixed institutional sentiment despite Nutshell's reduction.
• Medpace recently beat earnings and revenue estimates with $4.67 EPS and 32% revenue growth, provided FY2026 EPS guidance of $16.68–17.50, and holds a consensus analyst rating of "Hold" with an average target of $486.67.

Nutshell Asset Management Ltd lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 54.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,712 shares of the company's stock after selling 22,217 shares during the period. Medpace accounts for about 4.6% of Nutshell Asset Management Ltd's holdings, making the stock its 10th biggest position. Nutshell Asset Management Ltd owned 0.07% of Medpace worth $9,621,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Mawer Investment Management Ltd. increased its holdings in shares of Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company's stock worth $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC raised its position in shares of Medpace by 15.1% in the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company's stock worth $193,269,000 after buying an additional 81,637 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company's stock worth $300,679,000 after buying an additional 62,503 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company's stock valued at $139,740,000 after buying an additional 45,435 shares during the period. Institutional investors own 77.98% of the company's stock.

Analyst Ratings Changes

MEDP has been the topic of a number of research analyst reports. Mizuho set a $582.00 target price on Medpace in a research note on Wednesday, February 11th. Leerink Partners lowered their price target on Medpace from $575.00 to $485.00 and set a "market perform" rating on the stock in a report on Wednesday, February 11th. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and set a $560.00 price target for the company in a research report on Friday, February 13th. BMO Capital Markets reissued a "market perform" rating on shares of Medpace in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada assumed coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an "outperform" rating and a $522.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average target price of $486.67.

Medpace Price Performance

Shares of MEDP opened at $470.59 on Monday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a 50 day simple moving average of $533.94 and a two-hundred day simple moving average of $539.47. The firm has a market cap of $13.36 billion, a P/E ratio of 30.76, a P/E/G ratio of 2.26 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same period in the previous year, the business posted $3.67 EPS. The business's quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.